SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Jain Foundation Clinical Study Exceeds Recruitment Goals

[April 02, 2014]

Jain Foundation Clinical Study Exceeds Recruitment Goals

SEATTLE --(Business Wire)--

The Jain Foundation is delighted to announce that 193 patients have been recruited into the Clinical Outcome Study for Dysferlinopathy (COS), exceeding the original goal of 150 patients. Professor Kate Bushby, MD, at Newcastle University and Laura Rufibach, PhD, at the Jain Foundation are co-leading this multi-year study, running in 14 centers worldwide. The study is projected to cost over $3M (News - Alert) and is funded entirely by the Jain Foundation.

Dysferlinopathy, also called Limb Girdle Muscular Dystrophy type 2B (LGMD2B) or Miyoshi myopathy, is a rare genetic disease that causes progressive muscle weakness. "Because the normal disease progression has not yet been defined, the main goal of the Clinical Outcome Study is to measure disease progression in patients at all phases of the disease and to identify tests that can be used in clinical trials. This study is a critical step towards developing a therapy for this disease because it will make it possible to test the effectiveness of potential drugs and interventions," explains Dr. Rufibach.

"The recruitment of this large number of people affected by such a rare disease is a real indication of the dedication of the study teams and the enthusiasm of the patients to participate in research," said Professor Bushby. Dr. Plavi Mittl, President and CEO of the Jain Foundation, confirmed this saying, "Because we are testing as much as possible in this study, we are asking a lot from everyone, especially the patients. I am continually impressed by the commitment of the patients and staff at all of our 14 COS centers." The study centers are located in the United Kingdom, United States, Japan, Australia, Germany, France, Spain, and Italy. For more information about the study, visit www.jain-foundation.org/dysferlinoutcomestudy.


ABOUT DYSFERLINOPATHY (LGMD2B/MIYOSHI MYOPATHY)

Dysferlinopathy is a rare muscular dystrophy caused by mutations in the dysferlin gene. It has multiple clinical manifestations, the most common of which are Limb Girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. Muscle weakness typically begins in the late teens to early 20s and patients become wheelchair-bound approximately 10 years after the onset of muscle weakness.

ABOUT THE JAIN FOUNDATION

The Jain Foundation (www.jain-foundation.org) is a privately funded not-for-profit corporation based in Seattle. It is focused on finding a therapy for muscular dystrophies caused by dysferlin deficiency (LGMD2B/Miyoshi Myopathy).

ABOUT NEWCASTLE UNIVERSITY

Newcastle University is a public research university located in Newcastle upon Tyne in the United Kingdom. The dysferlin gene was first identified at Newcastle University by Prof Bushby's team. This 70-person muscle team based in the Institute of Genetic Medicine has a range of ongoing research projects focused on the delineation of the best care and new treatments available for muscular dystrophy and other rare diseases (www.treat-nmd.eu).


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.